Jean Caraux

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.